ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advances in Giant Cell Arteritis

Philip Seo, MD, MHS  |  Issue: December 2025  |  November 14, 2025

Secondary analyses demonstrated that, at week 52, more patients treated with tocilizumab were relapse free while tapering to prednisone ≤5 mg/d (81% vs. 56%). However, by week 78, approximately equal numbers of patients in both groups met this criterion (50% vs. 58%).

For patients with GCA treated with glucocorticoids for one year, we expect to see a relapse rate of approximately 50%. This subgroup analysis implies that patients treated with methotrexate experience many of these relapses upfront, whereas patients treated with tocilizumab do not begin to relapse in earnest until after they stop tocilizumab therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This study does not address whether methotrexate may be more effective as a remission-maintenance agent, following remission induction with tocilizumab.7 However, for those of us who have used methotrexate as a safe alternative to tocilizumab for remission induction in patients with GCA, methotrexate’s association with Pneumocystis infection and increased mortality is foreboding.

4. Vascular Ultrasound in GCA

Ni et al, Abstract 27028

Vascular ultrasound is becoming increasingly popular as an alternative to temporal artery biopsy for diagnosing GCA. However, the majority of data supporting its use was generated by physicians who performed the ultrasound themselves. The current study examined the efficacy of vascular ultrasound when performed by radiology technicians.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, 581 patients underwent vascular ultrasound; 80 of these patients (21.3%) had a confirmed clinical diagnosis of GCA after six months of follow-up. Using a clinical diagnosis of GCA as the gold standard, vascular ultrasound had a sensitivity of 21.3% and a specificity of 100%. The negative predictive value of vascular ultrasound was 82.4%.

When performed by an experienced clinician, vascular ultrasound has a sensitivity approaching temporal artery biopsy. However, the same cannot be said when the test is performed by a vascular ultrasound technician who may not have specific training in the assessment of GCA. Carotid arteries are assessed mainly based on flow dynamics, which are not useful when trying to determine if a patient has an inflamed temporal artery.

For years, rheumatologists have known that musculoskeletal ultrasound is most effective when performed by a clinician who understands the underlying disease and its pathology. It shouldn’t be surprising to learn that the same is true for temporal artery ultrasound.

5. Glucocorticoids vs. Glucocorticoids Plus Tocilizumab

De Boysson et al., Abstract 27049

Patients with GCA may have histopathologic evidence of arterial inflammation years after treatment initiation. Such patients are at higher risk of developing potentially life-threatening aneurysms.10 However, whether some therapies are more effective at extinguishing this chronic arterial inflammation has remained unclear.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAV FocusRheumACR Convergence 2025ANCA-Associated Vasculitisgiant cell arteritis (GCA)GlucocorticoidsimagingMagnetic resonance imaging (MRI)taperingupadacitinib

Related Articles

    Large Vessel Vasculitis

    December 1, 2023

    SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences